SG11201900794PA - Multivalent pneumococcal polysaccharide-protein conjugate composition - Google Patents

Multivalent pneumococcal polysaccharide-protein conjugate composition

Info

Publication number
SG11201900794PA
SG11201900794PA SG11201900794PA SG11201900794PA SG11201900794PA SG 11201900794P A SG11201900794P A SG 11201900794PA SG 11201900794P A SG11201900794P A SG 11201900794PA SG 11201900794P A SG11201900794P A SG 11201900794PA SG 11201900794P A SG11201900794P A SG 11201900794PA
Authority
SG
Singapore
Prior art keywords
pasteur
international
sanofi
drive
swiftwater
Prior art date
Application number
SG11201900794PA
Inventor
Kyungjun An
Wooyoung Choi
Dongsoo Ham
Hun Kim
Jinhwan Shin
Robert Hopfer
Richard Kensinger
Moe Kyaw
Eric Desauziers
Guerche Seblain Clotilde El
Philippe Talaga
Original Assignee
Sanofi Pasteur Inc
Sk Bioscience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc, Sk Bioscience Co Ltd filed Critical Sanofi Pasteur Inc
Publication of SG11201900794PA publication Critical patent/SG11201900794PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Abstract

1 N O cc O C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 February 2018 (08.02.2018) WIPO I PCT IiiimmounnotioloomoimmomomomovoimIE (10) International Publication Number WO 2018/027126 Al (51) International Patent Classification: A61K 39/00 (2006.01) A61K 39/385 (2006.01) A61K 39/09 (2006.01) A61K 39/39 (2006.01) A61K 39/116 (2006.01) (21) International Application Number: PCT/US2017/045483 (22) International Filing Date: 04 August 2017 (04.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/371,553 05 August 2016 (05.08.2016) US 62/525,945 28 June 2017 (28.06.2017) US (71) Applicants: SANOFI PASTEUR, INC. [US/US]; 1 Dis- covery Drive, Swiftwater, PA 18730 (US). SK CHEMI- CALS CO., LTD. [KR/KR]; Life Science Biz, 310, Pangyo-ro, Seongnam-si, Gyeonggi-do, 13494 (KR). (72) Inventors: AN, Kyungjun; 302, 8-19, Bangbae-ro 20- gil, Seocho-gu, Seoul, 06684 (KR). CHOI, Wooyoung; 805-1703, 52, Pungdeokcheon-ro, Suji-gu, Yongin-si, Gyeonggi-do, 16843 (KR). HAM, Dongsoo; 113-505, 373, Gwongwang-ro, Paldal-gu, Suwon-shi, Gyeonggi-do, 16493 (KR). KIM, Hun; 6114-2903, 76, Central Town- ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16505 (KR). SHIN, Jinhwan; 233-1201, 24, Jungdae-ro, Songpa-gu, Seoul, 05834 (KR). HOPFER, Robert; c/o Sanofi Pas- teur, 1 Discovery Drive, Swiftwater, PA 18730 (US). KENSINGER, Richard, D.; c/o Sanofi Pasteur, 1 Dis- covery Drive, Swiftwater, PA 18730 (US). KYAW, Moe; c/o Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA 18730 (US). DESAUZIERS, Eric; c/o Sanofi Pateur SA, 2, Avenue Pont Pasteur, 69367 Lyon Cedex 07 (FR). EL GUERCHE SEBLAIN, Clotilde; c/o Sanofi Pasteur SA, 2, Avenue Pont Pasteur, 69367 Lyon Cedex 07 (FR). TA- LAGA, Philippe; c/o Sanofi Pasteur SA, 2, Avenue Pont Pasteur, 69367 Lyon Cedex 07 (FR). (54) Title: MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION Mono-conjugate of Serotype 8 F- 2 0 350 300 250 200 150 100 50 0 8-1 (0.5 big) 8-1 (2.2 mg) 8-1 (8.8 iug) FIG. 1A (57) : Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 20 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRMig7, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject. [Continued on next page] WO 2018/027126 Al MIDEDIMOMMIDIIMERIONMOIDEEDHOHIMOVOIMIE (74) Agent: DONALDSON, Timothy, B.; MH2 Technology Law Group, 1951 Kidwell Drive, Suite 550, Tysons Corner, VA 22182 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11201900794PA 2016-08-05 2017-08-04 Multivalent pneumococcal polysaccharide-protein conjugate composition SG11201900794PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371553P 2016-08-05 2016-08-05
US201762525945P 2017-06-28 2017-06-28
PCT/US2017/045483 WO2018027126A1 (en) 2016-08-05 2017-08-04 Multivalent pneumococcal polysaccharide-protein conjugate composition

Publications (1)

Publication Number Publication Date
SG11201900794PA true SG11201900794PA (en) 2019-02-27

Family

ID=61073102

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900794PA SG11201900794PA (en) 2016-08-05 2017-08-04 Multivalent pneumococcal polysaccharide-protein conjugate composition

Country Status (15)

Country Link
US (1) US11241489B2 (en)
EP (1) EP3493837B1 (en)
JP (1) JP7001687B2 (en)
KR (1) KR102437120B1 (en)
CN (1) CN109862908B (en)
AU (1) AU2017306711B2 (en)
BR (1) BR112019001971A2 (en)
CA (1) CA3031799A1 (en)
IL (1) IL264552B2 (en)
MX (1) MX2019001342A (en)
PH (1) PH12019500240A1 (en)
SA (1) SA519401027B1 (en)
SG (1) SG11201900794PA (en)
TW (1) TWI789357B (en)
WO (1) WO2018027126A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303998A (en) * 2015-07-21 2023-08-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EA039427B1 (en) 2016-08-05 2022-01-26 Санофи Пастер Инк. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11090374B2 (en) * 2017-02-24 2021-08-17 Merck Sharp & Dohme Corp. Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
AU2018328038B2 (en) 2017-09-07 2024-03-07 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
AR114154A1 (en) 2017-12-06 2020-07-29 Merck Sharp & Dohme COMPOSITIONS INCLUDING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATES WITH PROTEIN AND METHODS OF USE OF THESE
AU2019215212A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
SG11202006388SA (en) * 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN111989114A (en) 2018-04-18 2020-11-24 Sk生物科学株式会社 Capsular polysaccharides of streptococcus pneumoniae and immunogenic conjugates thereof
CN108524926B (en) * 2018-06-29 2021-06-29 康希诺生物股份公司 Preparation combination of multivalent pneumococcal conjugate vaccine and application thereof
US11642406B2 (en) 2018-12-19 2023-05-09 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2020323498A1 (en) 2019-07-31 2022-03-03 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
WO2022031087A1 (en) * 2020-08-07 2022-02-10 (주)셀트리온 Immunogenic composition comprising pneumococcal polysaccharide-cell wall-derived material conjugates
KR20220102871A (en) * 2021-01-14 2022-07-21 (주)셀트리온 The immunogenic composition comprising multivalent pneumococcal polysaccharide-protein conjugate
KR20230047827A (en) * 2021-10-01 2023-04-10 에스케이바이오사이언스(주) Method for preparing an aluminum based adjuvant having improved effect

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (en) 1988-11-03 1990-05-04 Tino Dalto SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (en) 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
ATE245446T1 (en) 1992-02-11 2003-08-15 Jackson H M Found Military Med DUAL CARRIER FOR IMMUNOGENIC CONSTRUCTS
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
ATE280235T1 (en) 1993-03-05 2004-11-15 Wyeth Corp PLASMID FOR PRODUCING CRM PROTEIN AND DIPHTHERIA TOXIN
KR100376361B1 (en) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 How to activate soluble carbohydrates using new cyanating reagents for the production of immunogenic constructs
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
WO1996025425A1 (en) 1995-02-16 1996-08-22 Massachusetts Health Research Institute, Inc. Purified tetanus toxoid and toxin
WO1996029094A1 (en) 1995-03-22 1996-09-26 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
WO1996040225A1 (en) 1995-06-07 1996-12-19 Alberta Research Council Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
US5695768A (en) 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US5866132A (en) 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
CA2153730A1 (en) 1995-07-12 1997-01-13 Andrew J. Malcolm Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides
CA2153733A1 (en) 1995-07-12 1997-01-13 Andrew J. Malcolm Immunogenic oligosaccharide compositions
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (en) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
JP2002540074A (en) 1999-03-19 2002-11-26 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム vaccine
FR2806304B1 (en) * 2000-03-17 2002-05-10 Aventis Pasteur POLYSACCHARIDIC CONJUGATES OF PNEUMOCOCCUS FOR VACCINE USE AGAINST TETANUS AND DIPHTHERIA
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
ES2375704T5 (en) 2000-06-29 2016-03-03 Smithkline Beecham Biologicals S.A. Composition of multivalent vaccine
ES2359625T3 (en) 2000-12-28 2011-05-25 Wyeth Llc PROTECTIVE PROTEIN RECOMBINANT OF.
AU2007200116A1 (en) 2001-04-03 2007-02-01 Glaxosmithkline Biologicals S.A. Vaccine composition
EP1572868A4 (en) 2001-04-16 2007-04-04 Wyeth Corp Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
TWI346555B (en) 2002-04-01 2011-08-11 Glaxosmithkline Biolog Sa Vaccine composition
TWI341210B (en) 2002-04-01 2011-05-01 Glaxosmithkline Biolog Sa Vaccine kit
DE602004010376T2 (en) 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. PROCESS FOR CLEANING BACTERIAL CYTOLYSIN
US7320874B2 (en) 2003-07-08 2008-01-22 Aventis Pasteur Sa Assaying the teichoic acids of gram+ bacteria
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425855A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2707202T3 (en) 2005-04-08 2019-04-02 Wyeth Llc Separation of polysaccharide contaminants from Streptococcus pneumoniae by pH manipulation
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
MY148141A (en) 2005-12-22 2013-03-15 Glaxosmithkline Biolog Sa Vaccine
US8808707B1 (en) * 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
CN101522906B (en) 2006-10-10 2012-05-30 惠氏公司 Purification of streptococcus pneumoniae type 3 polysaccharides
US8652480B2 (en) 2007-03-23 2014-02-18 Wyeth Llc Shortened purification process for the production of capsular Streptococcus pneumoniae polysaccharides
EP2167120A2 (en) * 2007-06-26 2010-03-31 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
CA2757620C (en) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101785857B (en) 2010-03-05 2012-09-26 成都安特金生物技术有限公司 Novel pneumococcal conjugate vaccine and preparation method thereof
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
CN102068690A (en) 2010-12-31 2011-05-25 北京民海生物科技有限公司 Polyvalent pneumococcal capsular polysaccharide conjugate vaccine and preparation method thereof
KR102057217B1 (en) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
HUE049531T2 (en) 2012-08-16 2020-10-28 Pfizer Glycoconjugation processes and compositions
CN103656632B (en) 2012-09-24 2016-01-13 北京科兴中维生物技术有限公司 Multivalent pneumococcal capsular polysaccharide composition, its preparation method and application
CN103656631B (en) 2012-09-24 2015-08-19 北京科兴中维生物技术有限公司 multivalent pneumococcal capsular polysaccharide-protein conjugate composition and preparation method thereof
KR20140075196A (en) 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
ITMI20130142A1 (en) 2013-01-31 2014-08-01 Biosynth Srl GLYCOCOUGUGAR VACCINES INCLUDING BASIC UNITS OF AN EXPRIMENT MOLECULAR CONSTRUCTED MULTIPLE EPITHOPES INCORPORATED
BR112016015525A2 (en) * 2014-01-21 2017-10-24 Pfizer immunogenic compositions comprising conjugated capsular saccharide antigens and use
EP3096783B1 (en) 2014-01-21 2021-07-07 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
KR20210032013A (en) 2014-01-21 2021-03-23 화이자 인코포레이티드 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
CN107029225B (en) 2014-07-25 2020-08-11 武汉博沃生物科技有限公司 Conjugate vaccine and preparation method thereof
DK3244917T3 (en) 2015-01-15 2023-05-22 Pfizer Immunogenic compositions for use in pneumococcal vaccines
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
CN106140046B (en) 2016-07-06 2019-02-22 江南大学 Array induction field fluid reaction system and its application
EA039427B1 (en) 2016-08-05 2022-01-26 Санофи Пастер Инк. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019215212A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
SG11202006388SA (en) 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2020323498A1 (en) 2019-07-31 2022-03-03 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same

Also Published As

Publication number Publication date
IL264552B (en) 2022-12-01
AU2017306711A1 (en) 2019-02-14
MX2019001342A (en) 2019-07-04
JP7001687B2 (en) 2022-02-04
US20200237889A1 (en) 2020-07-30
EP3493837A4 (en) 2020-04-08
EP3493837A1 (en) 2019-06-12
CN109862908B (en) 2023-05-02
SA519401027B1 (en) 2022-07-19
KR102437120B1 (en) 2022-08-25
IL264552B2 (en) 2023-04-01
IL264552A (en) 2019-02-28
CN109862908A (en) 2019-06-07
WO2018027126A1 (en) 2018-02-08
KR20190055063A (en) 2019-05-22
EP3493837B1 (en) 2022-08-31
TW201808328A (en) 2018-03-16
AU2017306711B2 (en) 2022-08-04
BR112019001971A2 (en) 2019-05-07
PH12019500240A1 (en) 2019-10-21
US11241489B2 (en) 2022-02-08
JP2019526621A (en) 2019-09-19
CA3031799A1 (en) 2018-02-08
TWI789357B (en) 2023-01-11

Similar Documents

Publication Publication Date Title
SG11201900794PA (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
SG11201900789VA (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
SG11201908062QA (en) Insertion mechanism for drug delivery device
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201805120YA (en) Zika virus vaccine
SG11201810210UA (en) Engineered botulinum neurotoxins
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201806652RA (en) Method for fabricating an object
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201806485RA (en) Pyrrolobenzodiazepine conjugates
SG11201808125RA (en) Methods for solid tumor treatment
SG11201901545RA (en) Noncontact detection method of sleep stages and sleep-disordered breathing
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201803906PA (en) Control of cellular redox levels
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
NZ601711A (en) 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
SG11201407852PA (en) Beauty tool
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809341PA (en) Mobile robot
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901986SA (en) Process for the manufacture of a solid pharmaceutical adminstration form
SG11201903431SA (en) Sstr-targeted conjugates and particles and formulations thereof
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof